Howard Zisser1, Eyal Dassau2, Justin J Lee3, Rebecca A Harvey3, Wendy Bevier4, Francis J Doyle2. 1. Sansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA hzisser@gmail.com. 2. Sansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA Institute for Collaborative Biotechnologies, University of California, Santa Barbara, Santa Barbara, CA, USA. 3. Sansum Diabetes Research Institute, Santa Barbara, CA, USA Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA. 4. Sansum Diabetes Research Institute, Santa Barbara, CA, USA.
Abstract
OBJECTIVE: The purpose of this study was to investigate whether or not adding a fixed preprandial dose of inhaled insulin to a fully automated closed loop artificial pancreas would improve the postprandial glucose control without adding an increased risk of hypoglycemia. RESEARCH DESIGN AND METHODS: Nine subjects with T1DM were recruited for the study. The patients were on closed-loop control for 24 hours starting around 4:30 pm. Mixed meals (~50 g CHO) were given at 6:30 pm and 7:00 am the following day. For the treatment group each meal was preceded by the inhalation of one 10 U dose of Technosphere Insulin (TI). Subcutaneous insulin delivery was controlled by a zone model predictive control algorithm (zone-MPC). At 11:00 am, the patient exercised for 30 ± 5 minutes at 50% of predicted heart rate reserve. RESULTS: The use of TI resulted in increasing the median percentage time in range (70-180 mg/dl, BG) during the 5-hour postprandial period by 21.6% (81.6% and 60% in the with/without TI cases, respectively, P = .06) and reducing the median postprandial glucose peak by 33 mg/dl (172 mg/dl and 205 mg/dl in the with and without TI cases, respectively, P = .004). The median percentage time in range 80-140 mg/dl during the entire study period was 67.5% as compared to percentage time in range without the use of TI of 55.2% (P = .03). CONCLUSIONS: Adding preprandial TI (See video supplement) to an automated closed-loop AP system resulted in superior postprandial control as demonstrated by lower postprandial glucose exposure without addition hypoglycemia.
OBJECTIVE: The purpose of this study was to investigate whether or not adding a fixed preprandial dose of inhaled insulin to a fully automated closed loop artificial pancreas would improve the postprandial glucose control without adding an increased risk of hypoglycemia. RESEARCH DESIGN AND METHODS: Nine subjects with T1DM were recruited for the study. The patients were on closed-loop control for 24 hours starting around 4:30 pm. Mixed meals (~50 g CHO) were given at 6:30 pm and 7:00 am the following day. For the treatment group each meal was preceded by the inhalation of one 10 U dose of Technosphere Insulin (TI). Subcutaneous insulin delivery was controlled by a zone model predictive control algorithm (zone-MPC). At 11:00 am, the patient exercised for 30 ± 5 minutes at 50% of predicted heart rate reserve. RESULTS: The use of TI resulted in increasing the median percentage time in range (70-180 mg/dl, BG) during the 5-hour postprandial period by 21.6% (81.6% and 60% in the with/without TI cases, respectively, P = .06) and reducing the median postprandial glucose peak by 33 mg/dl (172 mg/dl and 205 mg/dl in the with and without TI cases, respectively, P = .004). The median percentage time in range 80-140 mg/dl during the entire study period was 67.5% as compared to percentage time in range without the use of TI of 55.2% (P = .03). CONCLUSIONS: Adding preprandial TI (See video supplement) to an automated closed-loop AP system resulted in superior postprandial control as demonstrated by lower postprandial glucose exposure without addition hypoglycemia.
Authors: Marc Breton; Anne Farret; Daniela Bruttomesso; Stacey Anderson; Lalo Magni; Stephen Patek; Chiara Dalla Man; Jerome Place; Susan Demartini; Simone Del Favero; Chiara Toffanin; Colleen Hughes-Karvetski; Eyal Dassau; Howard Zisser; Francis J Doyle; Giuseppe De Nicolao; Angelo Avogaro; Claudio Cobelli; Eric Renard; Boris Kovatchev Journal: Diabetes Date: 2012-06-11 Impact factor: 9.461
Authors: K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter Journal: J Clin Invest Date: 1988-02 Impact factor: 14.808
Authors: K Rave; E Potocka; L Heinemann; T Heise; A H Boss; M Marino; D Costello; R Chen Journal: Diabetes Obes Metab Date: 2009-05-19 Impact factor: 6.577
Authors: Gregory P Forlenza; Sunil Deshpande; Trang T Ly; Daniel P Howsmon; Faye Cameron; Nihat Baysal; Eric Mauritzen; Tatiana Marcal; Lindsey Towers; B Wayne Bequette; Lauren M Huyett; Jordan E Pinsker; Ravi Gondhalekar; Francis J Doyle; David M Maahs; Bruce A Buckingham; Eyal Dassau Journal: Diabetes Care Date: 2017-06-05 Impact factor: 19.112
Authors: Alfonso Galderisi; Nathan Cohen; Peter Calhoun; Kristen Kraemer; Marc Breton; Stuart Weinzimer; Eda Cengiz Journal: Diabetes Care Date: 2020-07-13 Impact factor: 19.112
Authors: Alejandro J Laguna Sanz; Christopher M Mulla; Kristen M Fowler; Emilie Cloutier; Allison B Goldfine; Brett Newswanger; Martin Cummins; Sunil Deshpande; Steven J Prestrelski; Poul Strange; Howard Zisser; Francis J Doyle; Eyal Dassau; Mary-Elizabeth Patti Journal: Diabetes Technol Ther Date: 2018-02 Impact factor: 6.118
Authors: Lauren M Huyett; Trang T Ly; Gregory P Forlenza; Suzette Reuschel-DiVirgilio; Laurel H Messer; R Paul Wadwa; Ravi Gondhalekar; Francis J Doyle; Jordan E Pinsker; David M Maahs; Bruce A Buckingham; Eyal Dassau Journal: Diabetes Technol Ther Date: 2017-05-01 Impact factor: 6.118